Asymptomatic Severe Carotid Stenosis: Optimizing Medical Therapy Before the Procedural Conversation
CREST-2 has now reported, and it compared revascularization against intensive medical therapy — but he has never actually received the intensive regimen that formed the trial's comparison arm.
F.B., a 70-year-old man, a retired schoolteacher, came in for a routine physical and left with a referral he hadn't expected — his physician heard a bruit over his right carotid artery, ordered an ultrasound, and found an 80% stenosis in a man who has never had a stroke, a transient ischemic attack, or any neurologic symptom he's aware of. He has hypertension, treated but not tightly controlled, and has been on a moderate-intensity statin for years without anyone recently revisiting whether that's still the right dose.
Asymptomatic severe carotid stenosis used to be a more straightforward referral for endarterectomy or stenting, back when the trials establishing procedural benefit, ACAS and ACST-1, were run in an era of less aggressive medical therapy than exists now. Since then, high-intensity statins, better blood pressure control, and more consistent antiplatelet use have measurably lowered the annual stroke risk in medically managed asymptomatic carotid disease, which is what CREST-2 was designed to test. Its results, reported in late 2025, were split: among roughly 2,485 patients with stenosis of 70% or greater, adding carotid stenting to intensive medical therapy significantly reduced the primary endpoint of stroke or death (2.8% versus 6.0% at four years), while adding endarterectomy did not (3.7% versus 5.3%, not significant). That answer is not equipoise, but it is conditional: the medical arm CREST-2 measured against was an actively managed, protocol-driven regimen, and that distinction is where his case actually sits. His statin isn't at high intensity, and his blood pressure runs above target more often than his chart suggests anyone has pushed to fix. Before his team can honestly weigh CEA or CAS against medical therapy using CREST-2's numbers, they need to know what his risk looks like on the regimen CREST-2's control arm actually received.
In clinic, after the incidental finding
I want to be accurate about what the current evidence says, because it isn't 'medical therapy is enough.' CREST-2 tested exactly this question and found stenting plus intensive medical therapy beat intensive medical therapy alone, while endarterectomy did not. What that trial does not tell us is how a patient does on a regimen he has never actually been given — his statin isn't high-intensity, his blood pressure isn't controlled, and he's on no antiplatelet at all. He is currently receiving less than either arm of that trial.
If he were already on maximized therapy — high-intensity statin, blood pressure clearly at target, appropriate antiplatelet coverage — and still had 80% stenosis, I'd be referring him for stenting on CREST-2's strength without much argument. The case for optimizing first exists because he isn't there yet, not because I think the trial's result is in doubt.
I agree completely, and I'd add that this is overdue regardless of the carotid finding — his blood pressure has been running above target for longer than this referral has existed. I'd move him to high-intensity statin therapy, intensify his antihypertensive regimen, and start low-dose aspirin, then reassess his actual risk picture once he's genuinely on the regimen CREST-2's control arm received.
The one thing I wouldn't do is treat optimization as a reason to delay the procedural conversation indefinitely — 80% stenosis is still a real finding, and if his risk remains high enough even on optimized therapy, referral for CEA or CAS should proceed without further delay at that point.
I'd set a defined interval — three months — on optimized medical therapy: high-intensity statin, blood pressure genuinely at target, low-dose aspirin, before revisiting whether intervention adds meaningful benefit for him specifically. That gives us an actual answer about his risk on the regimen the modern evidence is built around, rather than either defaulting to a procedure based on older trial data or assuming medical therapy alone is sufficient before it's actually been tried.
Agreed: high-intensity statin started, antihypertensive regimen intensified toward a target below 130/80, low-dose aspirin added, and a 3-month reassessment of his actual risk on optimized therapy before revisiting the procedural conversation.
The stenting conversation is revisited with his on-treatment risk actually known, weighed against CREST-2's reported stenting benefit.
Referral for CEA or CAS proceeds, now on a much stronger evidentiary footing than it would have today.
His blood pressure and lipid panel will be rechecked at the 3-month mark specifically, not folded into his next routine annual visit.